WAYNE, Pa.--(BUSINESS WIRE)--Covalent Group, Inc. (Nasdaq: CVGR), a leader in the design, development, and management of complex clinical trials and patient registries for many of the world’s leading pharmaceutical and biotechnology companies, announced today that its shareholders have approved all seven proposals contained in its 2006 proxy including the issuance of additional shares of Covalent common stock in connection with the consummation of the business combination agreement with Remedium Oy, a privately owned, full-service contract research organization (CRO) based in Espoo, Finland. The vote to approve the issuance of the additional shares took place today at the Company’s Annual Meeting in Wayne, PA. The transaction is expected to close on November 1, 2006.
